secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0000950170-23-040653
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

4DMT reports Q2 net loss $29.6M; cash $310M; positive interim data for 4D-150 and 4D-710; Astellas deal
--------------------------------------------------------------------------------

- Q2 net loss $29.6M ($28.1M prior year); R&D expense $23.6M; cash $310M as of June 30, 2023.
- Cash includes $129M net public offering proceeds and $20M Astellas upfront; expected to fund into H1 2026.
- Positive interim 4D-150 data: 100% reduction in anti-VEGF injections at high dose; durable response >1 year.
- Phase 2 Dose Expansion of 4D-150 completed enrollment of 50 patients nearly two quarters ahead of schedule.
- License with Astellas: $20M upfront, up to $942.5M milestones plus royalties for R100 vector in rare ophthalmic diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000095017023040653/0000950170-23-040653-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000095017023040653/fdmt-20230809.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-040653

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer